ESLA

Estrella Immunopharma, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.52

Price (1 Year)

$2.11 $0.38

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %2.1 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Website

Analysis (Turkish): ESLA Hissesi Caiz mi, Helal mi? Estrella Immunopharma, Inc. Katılım Analizi